- Home
- STKS vs CTNM Comparison
STKS vs CTNM Comparison
Compare STKS & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- CTNM
- Stock Information
- Founded
- STKS 2004
- CTNM 2009
- Country
- STKS United States
- CTNM United States
- Employees
- STKS N/A
- CTNM N/A
- Industry
- STKS Restaurants
- CTNM
- Sector
- STKS Consumer Discretionary
- CTNM
- Exchange
- STKS Nasdaq
- CTNM Nasdaq
- Market Cap
- STKS 112.2M
- CTNM 122.9M
- IPO Year
- STKS N/A
- CTNM 2024
- Fundamental
- Price
- STKS $3.43
- CTNM $4.76
- Analyst Decision
- STKS Buy
- CTNM Strong Buy
- Analyst Count
- STKS 2
- CTNM 4
- Target Price
- STKS $4.25
- CTNM $22.50
- AVG Volume (30 Days)
- STKS 58.7K
- CTNM 119.1K
- Earning Date
- STKS 08-05-2025
- CTNM 08-12-2025
- Dividend Yield
- STKS N/A
- CTNM N/A
- EPS Growth
- STKS N/A
- CTNM N/A
- EPS
- STKS N/A
- CTNM N/A
- Revenue
- STKS $799,478,000.00
- CTNM N/A
- Revenue This Year
- STKS $28.67
- CTNM N/A
- Revenue Next Year
- STKS $5.12
- CTNM N/A
- P/E Ratio
- STKS N/A
- CTNM N/A
- Revenue Growth
- STKS 138.50
- CTNM N/A
- 52 Week Low
- STKS $2.37
- CTNM $3.35
- 52 Week High
- STKS $5.42
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- STKS 46.52
- CTNM N/A
- Support Level
- STKS $3.35
- CTNM N/A
- Resistance Level
- STKS $3.80
- CTNM N/A
- Average True Range (ATR)
- STKS 0.29
- CTNM 0.00
- MACD
- STKS -0.04
- CTNM 0.00
- Stochastic Oscillator
- STKS 34.57
- CTNM 0.00
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.